Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218924 | 0.90 | HDAC1 (0.47) | HDAC1HDAC6 | |
| SCHEMBL3989232 | 0.84 | CACNA1H (0.46) | CACNA1HMEN1KMT2ASTSHTT | |
| SCHEMBL14263479 | 0.84 | MEN1 (0.43) | CACNA1HMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL8213940 | 0.83 | CACNA1H (0.59) | CACNA1HMEN1KMT2ASTSHTT | |
| SCHEMBL8207195 | 0.82 | HDAC1 (0.43) | CACNA1HMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL14263432 | 0.80 | CACNA1H (0.54) | CACNA1HMEN1KMT2A | |
| SCHEMBL8213185 | 0.80 | CACNA1H (0.41) | CACNA1HHDAC1HDAC6 | |
| SCHEMBL4412451 | 0.80 | CACNA1H (0.59) | CACNA1HMEN1KMT2ASTSHTT | |
| SCHEMBL26818759 | 0.80 | MEN1 (0.45) | MEN1KMT2ASTSHTTSMN1; SMN2 | |
| SCHEMBL26822130 | 0.80 | MDM2 (0.42) | CACNA1HKMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | CACNA1H 2829/4885MEN1 1687/4885KMT2A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.